<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186810</url>
  </required_header>
  <id_info>
    <org_study_id>SCALLO</org_study_id>
    <nct_id>NCT00186810</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation From HLA/MLC Genotype Identical Donors for Patients With High Risk Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol studied the effect of administration of a myeloablative pretransplant&#xD;
      preparative regimen followed by an infusion of donor stem cells in children with severe&#xD;
      sickle cell disease. The donor graft consisted of bone marrow or cord blood derived from a&#xD;
      genetically matched sibling.&#xD;
&#xD;
      The primary aim of the study was to evaluate how well the donated cells migrated to the bone&#xD;
      marrow and begin producing healthy red blood cells, white blood cells and platelets&#xD;
      (engrafted), how well the recipients immune system recovered, and assess any regimen related&#xD;
      toxicities including a potentially life-threatening transplant related complication called&#xD;
      graft-versus-host-disease or GVHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this protocol evaluated the effect of this transplant procedure&#xD;
      on the subsequent clinical course of patients with severe SCD. Specifically, to determine&#xD;
      whether pre-transplant organ dysfunction (brain, heart, lung, kidney, liver, spleen, etc)&#xD;
      resultant from sickle hemoglobinopathy can be reversed following this particular transplant&#xD;
      procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1992</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate engraftment, GVHD, hematopoietic and immune reconstitution, and regimen-related mortality and morbidity in patients with severe sickle cell disease undergoing transplant using either HLA matched sibling bone marrow or cord blood grafts.</measure>
    <time_frame>March 2007</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan, Cyclophosphamide, Horse ATG</intervention_name>
    <description>Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic stem cell transplant</intervention_name>
    <description>Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Diagnosis of severe' disease is denoted by one of the following:&#xD;
&#xD;
          -  Previous central nervous system vaso-occlusive episode with or without residual&#xD;
             neurologic findings or&#xD;
&#xD;
          -  Frequent painful vaso-occlusive episodes with significant interference with normal&#xD;
             life activities and which necessitates chronic transfusion therapy or&#xD;
&#xD;
          -  Recurrent SCD chest syndrome events which necessitate chronic transfusion therapy.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient with SCD chronic lung disease greater than or equal to stage 3&#xD;
&#xD;
          -  Patient with severe renal dysfunction defined as creatinine clearance &lt; 40&#xD;
             ml/min/1.73m2.&#xD;
&#xD;
          -  Patient with severe cardiac dysfunction defined as echocardiogram shortening fraction&#xD;
             &lt; 25%.&#xD;
&#xD;
          -  Patient with HIV infection.&#xD;
&#xD;
          -  Pregnant or lactating.&#xD;
&#xD;
          -  Patient with unspecified chronic toxicity that in the opinion of the Principal&#xD;
             Investigator is serious enough to detrimentally affect the patient's capacity to&#xD;
             tolerate SCT.&#xD;
&#xD;
          -  Patient or patient's guardian(s) unable to understand the nature and risks inherent in&#xD;
             the BMT process&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Hale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>May 28, 2009</last_update_submitted>
  <last_update_submitted_qc>May 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gregory Hale, MD / Principal Investigator</name_title>
    <organization>St. Jude Children's Research Hospital</organization>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Sickle Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

